[
  {
    "ts": null,
    "headline": "How HP, Merck And Virtus Investment Partners Can Put Cash In Your Pocket",
    "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. HP, Merck and Virtus Investment Partners have rewarded shareholders for decades and recently announced dividend increases. ...",
    "url": "https://finnhub.io/api/news?id=9bb49e45cefbf0245e0edf6687aa5a7d8c955f77f985b8ea01107c021d66700c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734033614,
      "headline": "How HP, Merck And Virtus Investment Partners Can Put Cash In Your Pocket",
      "id": 131939885,
      "image": "https://media.zenfs.com/en/benzinga_79/cd81b0747280131f5e17d382e8dddbca",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. HP, Merck and Virtus Investment Partners have rewarded shareholders for decades and recently announced dividend increases. ...",
      "url": "https://finnhub.io/api/news?id=9bb49e45cefbf0245e0edf6687aa5a7d8c955f77f985b8ea01107c021d66700c"
    }
  },
  {
    "ts": null,
    "headline": "Possible Bearish Signals With Merck Insiders Disposing Stock",
    "summary": "In the last year, many Merck & Co., Inc. ( NYSE:MRK ) insiders sold a substantial stake in the company which may have...",
    "url": "https://finnhub.io/api/news?id=92170edf569fbd176a7336ad6524a284689f012e41f358294f88c1419400e0aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734012023,
      "headline": "Possible Bearish Signals With Merck Insiders Disposing Stock",
      "id": 131939887,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "In the last year, many Merck & Co., Inc. ( NYSE:MRK ) insiders sold a substantial stake in the company which may have...",
      "url": "https://finnhub.io/api/news?id=92170edf569fbd176a7336ad6524a284689f012e41f358294f88c1419400e0aa"
    }
  },
  {
    "ts": null,
    "headline": "14 Upcoming Dividend Increases",
    "summary": "Discover top dividend growth stocks like PHM and LDOS, outperforming ETF benchmarks.",
    "url": "https://finnhub.io/api/news?id=3f174be170dadf16f99d912c6a4c7b972e9f1a02cc6d6cabacf6e0fb6f0fee77",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734003346,
      "headline": "14 Upcoming Dividend Increases",
      "id": 131930435,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/166422697/image_166422697.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover top dividend growth stocks like PHM and LDOS, outperforming ETF benchmarks.",
      "url": "https://finnhub.io/api/news?id=3f174be170dadf16f99d912c6a4c7b972e9f1a02cc6d6cabacf6e0fb6f0fee77"
    }
  },
  {
    "ts": null,
    "headline": "Spyre Therapeutics: Different Name, Same Tune",
    "summary": "Spyre Therapeutics, Inc. has promising assets in early-stage development, including SPY001, SPY002, and SPY003. Learn more about SYRE stock here.",
    "url": "https://finnhub.io/api/news?id=19b4257d0e8adf97242789a4cd5d1d188cb14963edbe7d3d55df3dd862fd531c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734002852,
      "headline": "Spyre Therapeutics: Different Name, Same Tune",
      "id": 131930294,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Spyre Therapeutics, Inc. has promising assets in early-stage development, including SPY001, SPY002, and SPY003. Learn more about SYRE stock here.",
      "url": "https://finnhub.io/api/news?id=19b4257d0e8adf97242789a4cd5d1d188cb14963edbe7d3d55df3dd862fd531c"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca and Merck - LYNPARZA Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial",
    "summary": "RAHWAY - AstraZeneca and Merck , known as MSD outside of the United States and Canada, today announced long-term results from the OlympiA Phase 3 trial which showed LYNPARZA demonstrated sustained,...",
    "url": "https://finnhub.io/api/news?id=7b2013ae0b566b502ce219eb2602e6925161af6632c841b0da6a8cbdc1ae6bfc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734001769,
      "headline": "AstraZeneca and Merck - LYNPARZA Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial",
      "id": 131929874,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "RAHWAY - AstraZeneca and Merck , known as MSD outside of the United States and Canada, today announced long-term results from the OlympiA Phase 3 trial which showed LYNPARZA demonstrated sustained,...",
      "url": "https://finnhub.io/api/news?id=7b2013ae0b566b502ce219eb2602e6925161af6632c841b0da6a8cbdc1ae6bfc"
    }
  },
  {
    "ts": null,
    "headline": "2 Ideal Buys From 50 'Safer' Dividends In 100 December Sustainables",
    "summary": "Among 78 dividend paying sustainable companies, 8 met the Dogcatcher ideal. Read more to see 2 ideal buys.",
    "url": "https://finnhub.io/api/news?id=a39a1aeb7a1a00a5a42db325c268a6bf78b8ad2c4925e395eaa981ac180c3c09",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733988906,
      "headline": "2 Ideal Buys From 50 'Safer' Dividends In 100 December Sustainables",
      "id": 131927671,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2170026993/image_2170026993.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Among 78 dividend paying sustainable companies, 8 met the Dogcatcher ideal. Read more to see 2 ideal buys.",
      "url": "https://finnhub.io/api/news?id=a39a1aeb7a1a00a5a42db325c268a6bf78b8ad2c4925e395eaa981ac180c3c09"
    }
  },
  {
    "ts": null,
    "headline": "Bueno And More Bueno",
    "summary": "The last time we looked into Bueno v Merck, it was anything but bueno. Taking the position that, if there is a cause of action, there must be jurisdiction, a misguided decision had held that a branded...",
    "url": "https://finnhub.io/api/news?id=a69d16a720db351bc06fe448ddaf2311f7fb50a43686b1ccc95d702a23beaf31",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733966165,
      "headline": "Bueno And More Bueno",
      "id": 131924514,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "The last time we looked into Bueno v Merck, it was anything but bueno. Taking the position that, if there is a cause of action, there must be jurisdiction, a misguided decision had held that a branded...",
      "url": "https://finnhub.io/api/news?id=a69d16a720db351bc06fe448ddaf2311f7fb50a43686b1ccc95d702a23beaf31"
    }
  }
]